Form 8-K

8-K — Microbot Medical Inc.

Accession: 0001493152-26-016293

Filed: 2026-04-13

Period: 2026-04-13

CIK: 0000883975

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000883975

2026-04-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 13, 2026

MICROBOT

MEDICAL INC.

(Exact

name of registrant as specified in its charter)

Delaware

000-19871

94-3078125

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

175

Derby St., Bld. 27

Hingham,

MA 02043

(Address

of Principal Executive Offices) (Zip Code)

Registrant’s

telephone number, including area code: (781) 875-3605

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

MBOT

NASDAQ Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

Growth Company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

April 13, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has successfully executed

the limited market release of the Company’s LIBERTY® Endovascular Robotic System (“LIBERTY”), and will

commence its full market release in the U.S. as planned at the Society of Interventional Radiology (SIR) Annual Scientific Meeting being

held in Toronto, ON, Canada, from April 11-15, 2026.

The

press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information

in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18

of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be

deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item

8.01 Other Events.

April 13, 2026, the Company announced that it has successfully executed the limited market release of LIBERTY, and will commence its

full market release in the U.S. as planned at the Society of Interventional Radiology (SIR) Annual Scientific Meeting being held in Toronto,

ON, Canada, from April 11-15, 2026. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their

networks, including hospitals such as Emory Healthcare and Tampa General Hospital. It has been successfully used commercially across

a variety of procedures, including Prostate Artery Embolization (PAE), Uterine Fibroid Embolization (UFE), Genicular Artery Embolization

(GAE), Y90 mapping, Y90 deliveries, and peripheral arterial interventions.

preparation for the full market release in the U.S., the Company has further enhanced its commercial team core capabilities by adding

salespeople in key locations and broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories

across the U.S. by the end of 2026.

Forward

Looking Statements

This

Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely

historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,”

“anticipates,” “expects,” “intends,” “would,” “could” and “estimates”)

are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future,

including but not limited to, regulatory milestones.

Actual

results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements

are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update

the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although

the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no

assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information

set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from

time-to-time with the Securities and Exchange Commission.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

99.1

Press Release

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By:

/s/

Harel Gadot

Name:

Harel Gadot

Title:

Chief Executive Officer, President

and Chairman

Date:

April 13, 2026

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

Microbot

Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at

the Society of Interventional Radiology (SIR) Annual Scientific Meeting

Successful

Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates

Broad Market Scalability in Key Endovascular Procedures

HINGHAM,

Mass., April 13, 2026 -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular

Robotic System, today announced that it has successfully executed its limited market release (LMR) and will commence its full market

release (FMR) in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their

networks, including globally recognized hospitals such as Emory Healthcare and Tampa General Hospital. Microbot considers this achievement

a reflection of the highly effective execution of the LIBERTY System’s LMR and positions the Company to commence the FMR of the

LIBERTY System as originally planned, at the Society of Interventional Radiology (SIR) Annual Scientific Meeting, being held in Toronto,

ON, Canada, from April 11-15.

The

LIBERTY system is creating an entirely new category as the only FDA-cleared, single-use, remotely operated robotic system. It has been

successfully used commercially across a variety of procedures, including Prostate Artery Embolization (PAE), Uterine Fibroid Embolization

(UFE), Genicular Artery Embolization (GAE), Y90 mapping, Y90 deliveries, and peripheral arterial interventions. Physicians have highlighted

LIBERTY’s precision, short learning curve, fast setup, the ability to use their preferred wires and catheters, as well as the potential

to improve efficiency by reducing procedure time and number of instruments used to perform such procedures.

preparation for the FMR, the Company has further enhanced its commercial team core capabilities by adding salespeople in key locations

and broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories across the U.S. by the

end of 2026.

“We

successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across

multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference,”

commented Harel Godot, Chairman, President & CEO. “It’s exciting to see the level of enthusiasm among our existing customers,

first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within

their network. The variety of case types shows the system’s flexibility, and its ease of use is generating high customer satisfaction.

I also believe the level of customer adoption during the limited market release in such a short time further demonstrates a shorter sales

cycle compared to traditional surgical robots, which is another key differentiator and one we believe will lead to accelerated adoption.”

SIR

represents over 8,000 practicing interventional radiology physicians, trainees, medical students, scientists, and clinical associates.

This will be the first opportunity for the Company to showcase the LIBERTY system at the conference, which features its primary addressable

U.S. target market.

SIR,

along with the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) have recently adopted new guidelines, which were

published in CardioVascular and Interventional Radiology (CVIR), and endorsed by at least eight other medical societies. These

guidelines cover updated evidence, address new exposure sources such as CT-guided procedures and radioembolization, and radiation protection

during pregnancy for female practitioners, as well as addresses musculoskeletal risks for interventional radiology staff. This follows

a recent American Medical Association (AMA) policy adopted late last year to strengthen protections for health care professionals from

occupational exposure to ionizing radiation.

“This

year’s SIR conference is a pivotal moment for Microbot Medical, and the timing of the conference represents an optimal opportunity

for our team to leverage the market feedback to commence the full market release of the LIBERTY System,” added Mr. Gadot. “Our

targeted end users will be in attendance, and we plan to engage with them directly, enhancing our opportunities over the coming months

as we broaden our presence in existing territories and expand into new ones.”

The

Company plans to meet with physicians and other stakeholders, to showcase the LIBERTY system

at booth #423, and to further educate physicians on the system’s full capabilities to accelerate market adoption in the U.S.

LIBERTY

is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise

vascular navigation while aiming to reduce radiation exposure and physical strain, addressing

key clinical and operational challenges faced by interventional radiology teams.

About

Microbot Medical

Microbot

Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced

robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use,

remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio

and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn

more at www.microbotmedical.com and connect on LinkedIn and X.

Safe

Harbor

Statements

to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development,

commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future

expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including,

but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,”

“intends,” “may,” “might,” “possible,” “potential,” “predicts,”

“projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,”

“expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but

the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,

including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular

Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory

pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes

in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from

new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual

property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors”

in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s

web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements,

except as required by law.

Contacts:

IR@microbotmedical.com

Media@microbotmedical.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (15941 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 13, 2026

Entity File Number

000-19871

Entity Registrant Name

MICROBOT

MEDICAL INC.

Entity Central Index Key

0000883975

Entity Tax Identification Number

94-3078125

Entity Incorporation, State or Country Code

Entity Address, Address Line One

175

Derby St.

Entity Address, Address Line Two

Bld. 27

Entity Address, City or Town

Hingham

Entity Address, State or Province

Entity Address, Postal Zip Code

02043

City Area Code

(781)

Local Phone Number

875-3605

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.01 par value

Trading Symbol

MBOT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration